Capital International Investors
GTHX

Capital International Investors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Capital International Investors’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-135,000
Closed -$2.58M – 398
2018
Q4 		$2.58M Sell
135,000
-130,000
-49% -$4.87M ﹤0.01% 369
2018
Q3 		$13.9M Buy
+265,000
New +$14.5M 0.01% 338

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Capital International Investors's GTHX Position: Q1 2019 in Review

Capital International Investors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2019, closing a stake of 135,000 shares — an estimated $2.58M sold.

Capital International Investors first reported a position in GTHX in Q3 2018 and held it in 2 quarters. The position peaked at $13.9M in Q3 2018. 93 funds tracked by Wall St. Rank hold GTHX as of Q1 2019.

  • Capital International Investors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Capital International Investors sold 135,000 G1 Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $2.58M.
  • Capital International Investors first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2018 and held it in 2 quarters.
  • Capital International Investors's G1 Therapeutics, Inc. Common Stock position peaked at $13.9M in Q3 2018.
  • 93 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Capital International Investors's 13F filing for Q1 2019, filed 15 May 2019.